You just read:

ImmunoCellular Therapeutics Receives Regulatory Approval in Canada, the UK and the Netherlands to Initiate ICT-107 Phase 3 Trial in Newly Diagnosed Glioblastoma

News provided by

ImmunoCellular Therapeutics, Ltd.

May 06, 2016, 06:00 ET